Canaglif100 mg

Canaglif is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with the following evidence-based indications:

Established/FDA-approved uses

• Glycemic control in type 2 diabetes mellitus: Canaglif is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.
• Cardiovascular risk reduction: Canaglif is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
• Diabetic nephropathy (kidney protection): Canaglif is indicated to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria.

Adjunct/combination use

Canaglif is commonly used in combination with other antidiabetic agents (metformin, sulfonylureas, insulin) when glycemic control is inadequate on a single agent, always alongside diet and exercise.

Each tablet contains Canagliflozin Hemihydrate equivalent to canagliflozin 100 mg or 300 mg, along with pharmaceutically acceptable excipients.

Canaglif is an orally administered sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus. It works by reducing renal glucose reabsorption, thereby lowering blood glucose levels independent of insulin secretion or action.

Beyond glycemic control, Canaglif has demonstrated cardiovascular and renal protective effects in large clinical outcome trials, making it a valuable option for patients with type 2 diabetes who also have established cardiovascular disease or diabetic kidney disease.

Canaglif belongs to the class of oral antidiabetic drugs known as SGLT2 (sodium-glucose cotransporter 2) inhibitors, sometimes referred to as 'gliflozins'.

Canagliflozin Hemihydrate inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, which is responsible for reabsorbing the majority of filtered glucose from the tubular lumen back into the bloodstream.

By blocking SGLT2, Canagliflozin Hemihydrate reduces renal glucose reabsorption and lowers the renal threshold for glucose, leading to increased urinary glucose excretion. This mechanism is insulin-independent, so Canagliflozin Hemihydrate lowers blood glucose without directly causing insulin release or increasing insulin resistance.

Additional effects include mild osmotic diuresis and natriuresis, which contribute to modest reductions in blood pressure and body weight, and are thought to underlie some of the observed cardiovascular and renal benefits.

Peak plasma concentrations occur within 1-2 hours after oral administration; Canagliflozin Hemihydrate is highly protein bound and is metabolized mainly via glucuronidation (UGT1A9 and UGT2B4), with a terminal half-life of approximately 10.6 hours (100 mg dose) to 13.1 hours (300 mg dose), permitting once-daily dosing.

Canaglif tablets should be swallowed whole with water, taken once daily before the first meal of the day, at approximately the same time each day.

The following are well-established, clinically significant interactions with Canaglif:

• UGT enzyme inducers (e.g., rifampin, phenytoin, phenobarbital, ritonavir): These may reduce plasma concentrations of Canaglif, potentially reducing efficacy; a dose increase to 300 mg once daily may be considered in patients tolerating Canaglif who require additional glycemic control and can safely take a higher dose.
• Insulin and insulin secretagogues (e.g., sulfonylureas): Concomitant use increases the risk of hypoglycemia; a lower dose of the insulin or secretagogue may be required.
• Digoxin: Canaglif modestly increases plasma digoxin concentrations; patients on digoxin should be monitored appropriately.
• Diuretics: Concomitant use may increase the risk of volume depletion and hypotension.

Common side effects of Canaglif include:

• Female genital mycotic infections (vulvovaginal candidiasis) and male genital mycotic infections (balanitis)
• Urinary tract infections
• Increased urination and thirst
• Constipation, nausea
• Increased LDL cholesterol

Less common but serious side effects requiring prompt medical attention include diabetic ketoacidosis, acute kidney injury, hyperkalemia, hypotension/volume depletion, necrotizing fasciitis of the perineum (Fournier's gangrene), bone fracture, lower-limb amputation, and hypersensitivity reactions (see Precautions and Warnings).

Pregnancy: Data on the use of Canaglif in pregnant women are limited. Based on its mechanism of action, Canaglif may affect fetal renal development, particularly during the second and third trimesters. Canaglif should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician should be consulted, and alternative antidiabetic therapy is generally preferred once pregnancy is confirmed.

Lactation: It is not known whether Canaglif is excreted in human breast milk, but based on animal data suggesting presence in milk and potential effects on renal development, use during breastfeeding is not recommended. A physician should be consulted to weigh the benefits of breastfeeding against the theoretical risk to the infant.

The following precautions and warnings apply to Canaglif:

• Lower-limb amputation: An increased risk of lower-limb amputation (most often of the toe or midfoot, though also more proximal) has been observed with Canaglif. Patients should be monitored for new pain or tenderness, sores, ulcers, or infections in the legs or feet, and Canaglif should be discontinued if these occur.
• Diabetic ketoacidosis (DKA): Canaglif can cause ketoacidosis, which may present with only modestly elevated glucose levels ("euglycemic DKA"), a recognized class effect of SGLT2 inhibitors. Symptoms include nausea, vomiting, abdominal pain, fatigue, and difficulty breathing. Canaglif should be temporarily discontinued in situations known to predispose to ketoacidosis (e.g., prolonged fasting, acute illness, surgery).
• Discontinuation before surgery: Canaglif should be discontinued, per current clinical guidance, at least 3 days before scheduled surgery to reduce the risk of perioperative ketoacidosis, and restarted once renal function and oral intake are stable.
• Genital mycotic infections and urinary tract infections: Increased risk due to glycosuria; patients should be counseled on hygiene and prompt reporting of symptoms.
• Volume depletion and hypotension: Canaglif causes intravascular volume contraction; caution is advised in elderly patients, patients with renal impairment, low systolic blood pressure, or those on diuretics or antihypertensives.
• Necrotizing fasciitis of the perineum (Fournier's gangrene): A rare but serious and life-threatening infection has been reported with SGLT2 inhibitors, including Canaglif. Patients presenting with pain, tenderness, erythema, or swelling in the genital or perineal area, with fever or malaise, should seek immediate medical attention; Canaglif should be discontinued if suspected.
• Bone fracture: An increased risk of bone fracture has been observed; bone health should be assessed in at-risk patients.
• Hyperkalemia: May occur, particularly in patients with renal impairment or those taking medications that interfere with potassium excretion.
• Hypersensitivity reactions: See Contraindications.

There is no specific antidote for Canaglif overdose. In case of a suspected overdose, seek immediate medical attention or contact a poison control center. Management should include general supportive measures based on the patient's clinical status, including monitoring of blood glucose, renal function, electrolytes, and hydration status. Excess glucose can be removed via hemodialysis in patients with adequate renal function to permit it, under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Canaglif requires dose consideration based on eGFR and is contraindicated in severe renal impairment, end-stage renal disease, or dialysis (see Contraindications and Dosage and Administration).

Hepatic impairment: No dosage adjustment needed in mild-to-moderate hepatic impairment; use in severe hepatic impairment is not recommended due to lack of data.

Elderly: Elderly patients, especially those 75 years and older, are at higher risk for volume-depletion-related adverse effects and should be monitored closely.

Pediatric use: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation.

Canaglif is generally used long-term as part of ongoing management of type 2 diabetes mellitus and its cardiovascular/renal risk reduction, with the duration determined by the treating physician based on glycemic response, tolerability, and overall treatment goals; it is not intended for short-term or as-needed use.

SGLT2 (sodium-glucose cotransporter 2) inhibitor; oral antidiabetic (gliflozin class).

Canagliflozin Hemihydrate selectively inhibits SGLT2 in the proximal renal tubules, reducing reabsorption of filtered glucose and lowering the renal threshold for glucose, which increases urinary glucose excretion and lowers blood glucose levels independent of insulin.

The safety and efficacy of Canaglif in pediatric patients under 18 years of age have not been established. Canaglif is therefore not recommended for use in children and adolescents.